Skip to main content

My account

Boston Scientific accounts are for healthcare professionals only.

Create an account to access online training and education on EDUCARE, manage your customer profile, and connect with customer support and service teams.

My Boston Scientific account

Access your online applications and manage your customer profile.

Quick Links

Call customer care

Shiny teal confetti

EKOS™ Endovascular System

The REAL-PE analysis

The truth about EKOS vs. FlowTriever™ in PE interventions

The REAL-PE analysis is the largest real-world and near real-time dataset evaluating advanced therapies for PE patients.

The results?  Patients treated with the EKOS system had statistically significant lower rates of major bleeding and intracerebral hemorrhage than patients treated with Inari Medical’s™ FlowTriever™ system. In fact, all studied safety events trended in favor of the EKOS system, as did 30-day all-cause readmission rates.1


Myths are Fragile: Beyond the Results of The REAL-PE Analysis

Go behind the scenes in this 5-part video series to hear from 3 of the authors of REAL-PE.

Hear from lead author Peter Monteleone, MD, as he discusses the REAL-PE analysis 

In comparison to patients who were treated with the FlowTriever System, patients treated with the EKOS system had a statistically significant:

Icon of blood drop

28%

 lower rate of major bleeding events*1
FlowTriever (n=118/682),
EKOS (n=195/1577), p=0.0018
 (ISTH Definition) 

Icon of brain hemorrhage

77%

 lower rate of intracerebral hemorrhage (0.3% incidence of ICH in patients treated with EKOS)*1
FlowTriever (n=9/682), EKOS (n=5/1577), p=0.005

Icon of hospital

Comparable in-hospital mortality rates (p=0.167), 30-day all-cause readmission rates (p=0.777), and median lengths of hospital stay*1

 


 

Indications, safety and warnings

*Calculated from published data cited below.

1. Monteleone P, et al. Modern Treatment of Pulmonary Embolism (USCDT versus MT): Results from Real-World, Big Data Analysis (REAL-PE). Journal of the Society for Cardiovascular Angiography & Interventions; Oct 2023.

Boston Scientific provided funding to Truveta for data reporting.

All trademarks are property of their respective owners.